Why Fundamental Investors Might Love Benitec Biopharma Limited (ASX:BLT)

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I look at stocks holistically, from their financial health to their future outlook. In the case of Benitec Biopharma Limited (ASX:BLT), it is a company that has been able to sustain great financial health, trading at an attractive share price. In the following section, I expand a bit more on these key aspects. If you’re interested in understanding beyond my broad commentary, take a look at the report on Benitec Biopharma here.

Flawless balance sheet and undervalued

BLT’s strong financial health means that all of its upcoming liability payments are able to be met by its current cash and short-term investment holdings. This implies that BLT manages its cash and cost levels well, which is an important determinant of the company’s health. Investors should not worry about BLT’s debt levels because the company has none! It has only utilized funding from its equity capital to run the business, which is typically normal for a small-cap company. BLT has plenty of financial flexibility, without debt obligations to meet in the short term, as well as the headroom to raise debt should it need to in the future. BLT’s share price is trading at below its true value, meaning that the market sentiment for the stock is currently bearish. Investors have the opportunity to buy into the stock to reap capital gains, if BLT’s projected earnings trajectory does follow analyst consensus growth, which determines my intrinsic value of the company. Compared to the rest of the biotechs industry, BLT is also trading below its peers, relative to earnings generated. This bolsters the proposition that BLT’s price is currently discounted.

ASX:BLT Price Estimation Relative to Market, July 20th 2019
ASX:BLT Price Estimation Relative to Market, July 20th 2019

Next Steps:

For Benitec Biopharma, there are three fundamental factors you should further examine:

  1. Future Outlook: What are well-informed industry analysts predicting for BLT’s future growth? Take a look at our free research report of analyst consensus for BLT’s outlook.
  2. Historical Performance: What has BLT’s returns been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
  3. Other Attractive Alternatives : Are there other well-rounded stocks you could be holding instead of BLT? Explore our interactive list of stocks with large potential to get an idea of what else is out there you may be missing!

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.